Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
328 participants
INTERVENTIONAL
2024-10-23
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Translated with DeepL.com (free version)
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Dapagliflozin on Recurrence After Catheter Ablation for Atrial Fibrillation
NCT06433479
Evaluation of Two Different Regimens of the Antiarrhythmic Drug Amiodarone to Maintain Normal Sinus Rhythm After Electrical Cardioversion in Patients With Persistent Atrial Fibrillation
NCT07273994
Study to Evaluate the Effect of Solifenacin and Mirabegron on the Digoxin Concentrations in Blood in Healthy Subjects
NCT02127034
Comparing the Effects of Amiodarone, Sotalol, and Placebo in Maintaining Sinus Rhythm in Patients With Atrial Fibrillation Converted to Sinus Rhythm
NCT00007605
Phase 2 Study of Oral K201 for Prevention of AF Recurrence
NCT01067833
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
experimental group
use Amiodarone, Bisoprolol and Digoxin
use Amiodarone, Bisoprolol and Digoxin
Amiodarone 200mg tid orally for 1 week, then reduced to 200mg bid orally for another week.
The dose of amiodarone will be reduced to 200mg bid orally for 1 week, and then 200mg qd maintenance treatment will be started in the 3rd week of dosing.
Bisoprolol 2.5-5mg qd oral treatment, the specific dose is decided by the investigator.
Digoxin 0.125mg qd orally.
control group
use Bisoprolol and Digoxin
use Amiodarone, Bisoprolol and Digoxin
Amiodarone 200mg tid orally for 1 week, then reduced to 200mg bid orally for another week.
The dose of amiodarone will be reduced to 200mg bid orally for 1 week, and then 200mg qd maintenance treatment will be started in the 3rd week of dosing.
Bisoprolol 2.5-5mg qd oral treatment, the specific dose is decided by the investigator.
Digoxin 0.125mg qd orally.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
use Amiodarone, Bisoprolol and Digoxin
Amiodarone 200mg tid orally for 1 week, then reduced to 200mg bid orally for another week.
The dose of amiodarone will be reduced to 200mg bid orally for 1 week, and then 200mg qd maintenance treatment will be started in the 3rd week of dosing.
Bisoprolol 2.5-5mg qd oral treatment, the specific dose is decided by the investigator.
Digoxin 0.125mg qd orally.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Anzhen Hospital
OTHER
Sir Run Run Shaw Hospital
OTHER
First Affiliated Hospital, Sun Yat-Sen University
OTHER
Nanfang Hospital, Southern Medical University
OTHER
Zhongshan People's Hospital, Guangdong, China
OTHER
The First Affiliated Hospital of Zhengzhou University
OTHER
Jiangmen Central Hospital
OTHER
Xiamen Cardiovascular Hospital
UNKNOWN
Yan 'an Hospital of Kunming City
UNKNOWN
Yumei Xue
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yumei Xue
Chief physician of the first area of the heart
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
202332
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.